Regeneron Pharmaceuticals is Biopharmaceutical Company focusing on the development of human antibody technologies for the treatment of a number of different diseases.
The company has two key antibody technology platforms from which it has created a number of potential drug candidates.
The drug products originating from the technologies all focus on diseases that span from oncology to ophthalmology and bone diseases. The main drugs developed by the company are:
- Eylea – Wet age-related macular degeneration
- Arcalyst - Cryopyrin-Associated Periodic Syndromes (CAPS)
- Zaltrap - Metastatic colorectal cancer
Regeneron whose motto is ‘science to medicine’ is currently listed at number 14 in the list of top 50 biotechnology companies has expanded significantly since its introduction to the pharmaceutical industry back in 1988 by neurologist Leonard S. Schleifer in New York who is now the company’s President and CEO. Just this year in 2014 Leonard has become a billionaire following the phenomenal success of Regeneron’s flagship eye product Eylea.
The company’s two pivotal antibody technologies have attracted a lot of attention from the pharma industry; the first technology is known as Regeneron TRAPS Technology; this technology has been developed to assist with the specificity and binding of human. The second technology attracting partners in the industry is VelocImmune™, a technology that is able to produce fully human monoclonal antibodies from a VelocImmune mouse. This technology has been brought in at just the right time, in an era where scientists are looking to monoclonal antibodies as the medical solution to certain diseases.
Big pharma deals
In the company’s short history it has managed to secure many big pharma deals; in its first year of opening it penned an agreement with Japanese based Sumitomo Chemical. This was followed by a VEGF Trap technology based collaboration with Proctor and Gamble and then with Bayer AG in 2006 to develop and commercialize the technology outside the USA. Finally in 2007 Sanofi Aventis joined the bandwagon and joined forces with Regeneron to discover and develop human antibodies using Regeneron’s VelocImmune Technology, this was after partnering with them initially in 2003 to develop the product ZALTRAP for intravenous injection. Top pharma company Astellas has taken out a licence to use Regeneron’s VelocImmune technology.
It seems that when it comes to partnering, Regeneron has created such irresistible timely technologies pharma companies have been keen to partner with them to develop the antibodies based on the technologies. Since 2009 the budding company has signed 18 partnering and licensing deals which is fairly impressive, as it continues to grow and get revenue from its products and partnerships it will no doubt start to acquire assets and or companies to build its company up as one of the top 5 biotechnology companies.
Regeneron Pharmaceuticals is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Regeneron Pharmaceuticals presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Regeneron Pharmaceuticals in person visit Current Partnering’s Event calendar.
Contacting Regeneron Pharmaceuticals for partnering
Regeneron Pharmaceuticals can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Regeneron Pharmaceuticals’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Regeneron Pharmaceuticals website has details for contacting Regeneron Pharmaceuticals .
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Regeneron Pharmaceuticals’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Regeneron Pharmaceuticals Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on the Regeneron Pharmaceuticals website for potential partnering opportunities and general contact names.
No M&A deals recorded for Regeneron Pharmaceuticals since 2009
Regeneron Pharmaceuticals partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Available reports from Current Partnering
Report: Partnering Agreements with Regeneron Pharmaceuticals 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Regeneron Pharmaceuticals
Read: more on Regeneron Pharmaceuticals company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk